Cancer Research UK. Prostate cancer incidence statistics [Internet]. [cited 2021 Feb 15]. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence
Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer. 2009;101:S115–24.
McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112:S108–15.
Hamilton W. Cancer diagnosis in primary care. Br J General Practice. 2010;60:121–8.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. The European randomized study of screening for prostate cancer-prostate cancer mortality at 13 years of follow-up HHS public access. Lancet. 2014;384:2027–35.
Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. J Am Med Assoc. 2018;319:883–95.
Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ. 2018;361:k1202.
Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015;107:1–4. h
Just J, Osgun F, Knight C. Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise? Br J General Practice; 2018;68:541–2.
Hamilton W, Sharp DJ, Peters TJ, Round AP. Clinical features of prostate cancer before diagnosis: a population-based, case-control study. Br J General Practice. 2006;56:756–62.
NICE: National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Ng12. 2017; https://www.nice.org.uk/guidance/ng12
Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20:54.
Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016;353:i3139.
Conti D v, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53:65–75.
Rashkin SR, Graff RE, Kachuri L, Thai KK, Alexeeff SE, Blatchins MA, et al. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun. 2020;11:1–14.
Fantus RJ, Helfand BT. Germline genetics of prostate cancer: time to incorporate genetics into early detection tools. Clin Chem. 2019;65:74–9.
Helfand B, Kearns J, Conran C, Xu J. Clinical validity and utility of genetic risk scores in prostate cancer. Asian J Androl. 2016;18:509–14.
Lewis C, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genom Med. 2020;12:44.
Manichaikul A, Mychaleckyj J, Rich S, Daly K, Sale M, Chen W. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26:2867–73.
Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The importance of anaemia in diagnosing colorectal cancer: a case–control study using electronic primary care records. Br J Cancer. 2008;98:323–7.
Bailey SER, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using UK electronic medical records and cancer registry data. Br J Gen Pract. 2017;67:e405–13.
Stapley S, Peters TJ, Neal RD, Rose PW, Walter FM, Hamilton W. The risk of oesophago-gastric cancer in symptomatic patients in primary care: A large case-control study using electronic records. Br J Cancer. 2013;108:25–31. https://doi.org/10.1038/bjc.2012.551.
Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton W. Clinical features of bladder cancer in primary care. Br J Gen Pract. 2012;62:e598–604.
Hopkins R, Bailey SER, Hamilton WT, Shephard EA. Microcytosis as a risk marker of cancer in primary care: A cohort study using electronic patient records. Br J Gen Pract. 2020;70:E457–62.
Shephard E, Neal R, Rose P, Walter F, Hamilton W. Clinical features of kidney cancer in primary care: a case-control study using primary care records. Br J Gen Pract. 2013;63:e250–5.
Price SJ, Shephard EA, Stapley SA, Barraclough K, Hamilton WT. Non-visible versus visible haematuria and bladder cancer risk: a study of electronic records in primary care. Br J Gen Pract. 2014;626:584–9.
Moore SF, Price SJ, Chowienczyk S, Bostock J, Hamilton W. The impact of changing risk thresholds on the number of people in England eligible for urgent investigation for possible cancer: an observational cross-sectional study. Br J Cancer. 2021;125:1593–7.
Banks J, Hollinghurst S, Bigwood L, Peters TJ, Walter FM, Hamilton W. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol. 2014;15:232–40.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.
Green HD, Merriel SWD, Oram RA, Ruth KS, Tyrrell J, Jones SE, et al. Applying a genetic risk score for prostate cancer to men withlower urinary tract symptoms in primary care to predict prostate cancerdiagnosis: a cohort study in the UK Biobank. 2022. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.21.22269629v1.
Hoffman RM, Frank D, Eley JW, Linda C, Stephenson RA, Stanford L, et al. Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:388–95.
Oto J, Fernández-Pardo Á, Royo M, Hervás D, Martos L, Vera-Donoso CD, et al. A predictive model for prostate cancer incorporating PSA molecular forms and age. Sci Rep. 2020;10:1–10.
Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:1–7.
Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112:S92–107.
Alderwick H, Dixon J. The NHS long term plan. BMJ. 2019;364:l84.
Genomics Education Programme. NHS launches new polygenic scores trial for heart disease [Internet]. 2021. https://www.genomicseducation.hee.nhs.uk/blog/nhs-launches-new-polygenic-scores-trial-for-heart-disease/
Our Future Health [Internet]. 2022. https://ourfuturehealth.org.uk/
Green H, Jones A, Evans J, Wood A, Beaumont R, Tyrrell J, et al. A genome-wide association study identifies 5 loci associated with frozen shoulder and implicates diabetes as a causal risk factor. PLoS Genet. 2021;17:e1009577.